ReviewAnnals of gastroenterological surgery2025
Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer.
Review in Annals of gastroenterological surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Perforated Gastric Cancer: Epidemiology, Diagnosis, and Surgical Management Strategies.Journal of clinical medicine · 2026Review
- Article
- Role of cuproptosis in digestive system tumors (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer remains a major global health burden, especially in East Asia. Recent years have brought significant advances in multimodal management, including surgery, perioperative chemotherapy, immunotherapy, and supportive care. This review summarizes key updates from 2023 to 2024, focusing on surgical innovations, perioperative systemic therapy, treatment strategies for stage IV disease, and nutritional interventions. In early and locally advanced disease, laparoscopic and robotic gastrectomy have become widely accepted in Asia, supported by large, randomized trials such as JCOG0912 and KLASS-02. Perioperative chemotherapy has become a global standard, with the FLOT regimen leading in the West and SOX, XELOX, or DOS emerging in Asia. Immunotherapy is increasingly incorporated into perioperative settings, with trials like KEYNOTE-585 and NEONIPIGA suggesting potential benefit in selected patients. For stage IV gastric cancer, systemic chemotherapy remains the mainstay, but conversion surgery and treatment of oligometastasis have shown promising results in selected cases. Trials such as JCOG1704 and AIO-FLOT5 are investigating optimal strategies. Perioperative nutrition has also gained attention, with oral nutritional supplements, ERAS protocols, and digital tools like continuous glucose monitoring (CGM) and AI-driven platforms enhancing outcomes. Looking ahead, integration of molecular biomarkers (e.g., HER2, PD-L1, MSI, ctDNA), precise staging, and multidisciplinary collaboration will be essential for personalized treatment. Ongoing trials and international cooperation are expected to further refine evidence-based approaches to gastric cancer care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.